S1537 |
Vadimezan (DMXAA)
|
Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3. |
-
Mol Cancer, 2024, 23(1):186
-
Nat Commun, 2024, 15(1):1750
-
Cell Rep Med, 2024, 5(7):101648
|
|
S6494 |
CCCP
|
CCCP (Carbonyl cyanide m-chlorophenyl hydrazone, Carbonyl cyanide 3-chlorophenylhydrazone), an oxidative phosphorylation inhibitor, is a protonophore mitochondrial uncoupler that increases membrane permeability to protons, leading to a disruption in the mitochondrial membrane potential. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), the protonophore, can inhibits STING-mediated IFN-β production via disrupting mitochondrial membrane potential (MMP). |
-
Nat Commun, 2024, 15(1):1785
-
Nat Commun, 2024, 15(1):1669
-
Redox Biol, 2024, 69:103002
|
|
S8133 |
Resiquimod (R-848)
|
Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2. |
-
Int J Nanomedicine, 2024, 19:3589-3605
-
Front Immunol, 2024, 15:1331480
-
Biology (Basel), 2023, 12(2)318
|
|
S7259 |
FLLL32
|
FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
|
-
Cancer Commun -Lond), 2023, 43(10):1117-1142
-
Microbiol Res, 2023, 276:127480
-
Pathol Oncol Res, 2022, 28:1610273
|
|
S3544 |
VBIT-4
|
VBIT-4 is a voltage-dependent anion channel (VDAC) oligomerization inhibitor that decreases mitochondrial DNA (mtDNA) release, type I interferon (IFN) signaling, neutrophil extracellular traps, and disease severity in a mouse model of systemic lupus erythematosus. |
-
Nature, 2023, 620(7973):374-380
-
Nature, 2023, 620(7973):374-380
-
Acta Pharm Sin B, 2023, 13(12):4765-4784
|
|
S3023 |
Bufexamac
|
Bufexamac(Bufexamic acid) is a COX inhibitor for IFN-α release with EC50 of 8.9 μM. |
-
Biomedicines, 2024, 12(6)1203
-
Int J Mol Sci, 2021, 22(9)4559
-
Reprod Sci, 2021, 10.1007/s43032-021-00533-2
|
|
S5588 |
Creatine
|
Creatine (Methylguanidoacetic acid) is a nitrogenous organic acid that occurs naturally in vertebrates. It facilitates the recycling of adenosine triphosphate (ATP) primarily in muscle and brain tissue.Creatine can inhibits the JAK-STAT1 signal transmission by inhibiting the interaction of IFN-γ receptors with JAK2 in an ATP-independent manner, thereby inhibiting downstream pro-inflammatory gene expression. |
-
Aging (Albany NY), 2022, 14(16):6796-6808
-
Cancer Cell, 2021, S1535-6108(21)00445-1
-
Histochem Cell Biol, 2021, 156(3):227-237
|
|
S3924 |
Ginsenoside Rb1
|
Ginsenoside Rb1 (Gypenoside Ⅲ) is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-obesity actions. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65. Ginsenoside Rb1 reduces the expressions of TLR3, TLR4 and TRAF-6, and down-regulates the levels of TNF-α, IFN-β and iNOS. |
-
J Biol Chem, 2024, 300(8):107542
-
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
-
J Biol Chem, 2021, S0021-9258(21)00790-0
|
|
S2259 |
Aloe-emodin
|
Aloe-emodin (NSC 38628, Rhabarberone) is an interferon-inducing agent with IC50 of about 1 μg/mL for JEV and of about 0.33 μg/mL for EV71. |
-
PLoS One, 2019, 14(4):e0215664
-
J Tradit Complement Med, 2015, 5(2):96-9
|
|
A2121 |
Anti-mouse IFNAR-1-InVivo
|
Anti-mouse IFNAR-1-InVivo monoclonal antibody (Clone: MAR1-5A3) reacts with mouse IFNAR-1 (IFN alpha/beta receptor subunit 1). Anti-mouse IFNAR-1-InVivo has been shown to inhibit Type I IFN receptor signaling in vitro and in vivo. |
-
Cell Rep, 2023, 42(1):112002
-
Signal Transduct Target Ther, 2022, 7(1):137
|
|
S8879 |
Deucravacitinib (BMS-986165)
|
Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases. |
-
Nat Commun, 2024, 15(1):1718
-
Nat Commun, 2024, 15(1):1337
-
Nat Commun, 2024, 15(1):7165
|
|
S0289 |
KIN1148
|
KIN1148 is an agonist of interferon regulatory factor 3 (IRF3) that induces dose-dependent IRF3 nuclear translocation and specific activation of IRF3-responsive promoters. KIN1148 is an influenza vaccine adjuvant that enhances flu vaccine efficacy. |
-
J Allergy Clin Immunol, 2022, S0091-6749(22)01423-3
|
|
S8954 |
G10 (STING agonist-1)
|
G10 (STING agonist-1) is a novel human-specific STING agonist that triggers IFN regulatory factor 3 (IRF3)/ type I interferon (IFN)-associated transcription in human fibroblasts. STING agonist-1 (G10) potently reduces growth of Chikungunya virus (CHIKV) with IC90 of 8.01 μM and blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM. |
-
Int J Biol Sci, 2023, 19(11):3428-3440
|
|
S0437 |
SAR-20347
|
SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling. |
-
Cancer Discov, 2023, 13(2):410-431
-
Cancer Discov, 2023, 13(2):410-431
|
|
S1833 |
Butoconazole nitrate
|
Butoconazole nitrate (RS-35887) is an anti-fungal agent that inhibits PHA-stimulated release of cytokines-- IL-2, TNFα, IFN and GM-CSF from human peripheral blood lymphocytes (IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively). |
|
|
E2982 |
IFN alpha-IFNAR-IN-1 hydrochloride
|
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor that inhibits the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) with IC50 value of 2-8 μM. |
|
|
A2152New |
Anti-mouse IFNγ (XMG1.2)-InVivo
|
Anti-mouse IFNγ (XMG1.2)-InVivo reacts with mouse IFNγ (interferon gamma) a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. |
-
Antib Ther, 2024, 7(3):266-280
|
|
A2867 |
Fontolizumab (Anti-IFNg)
|
Fontolizumab (anti-IFNg) is a humanized monoclonal antibody directed against interferon-gamma (IFN-g) with immunomodulatory activity. MW: 144.8. |
|
|
S3827 |
Royal jelly acid
|
Royal jelly acid (10-Hydroxy-trans-2-decenoic acid, 10H2DA) is the principal lipid component in royal jelly which is the food for queen and larvae honeybees. It is involved in several treatment processes of autoimmune and inflammatory diseases, including inhibition of lipopolysaccharide (LPS)- and interferon (IFN)-γ-stimulated macrophage responses, inhibition of T-cell proliferation and anti-rheumatoid activity. |
|
|
A2460 |
Anifrolumab (Anti-IFNAR1)
|
Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD. |
|
|
A2461 |
Sifalimumab (Anti-IFNa1)
|
Sifalimumab (Anti-IFNa1) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. MW: 145.5 KD. |
|
|
A2664 |
Rontalizumab (Anti-IFNa1)
|
Rontalizumab (Anti-IFNa1) is a humanized IgG1 monoclonal antibody targets IFN-α. It can be used for the research of systemic lupus erythematosus. MW :150 KD. |
|
|
S5020 |
Tilorone dihydrochloride
|
Tilorone dihydrochloride is a broad-spectrum, orally active antiviral agent that activates interferon production. It has antitumor, anti-inflammatory properties. |
|
|
S7904 |
2',3'-cGAMP Sodium Salt
|
2',3'-cGAMP Sodium Salt (2'-3'-cyclic GMP-AMP Sodium) is produced in response to DNA in the cytoplasm in mammalian cells and binds STING with high affinity and is an effective inducer of interferon-β (IFNβ). 2',3'-cGAMP binds to STING with Kd of 3.79 nM. |
-
Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0
-
Life Sci Alliance, 2024, 7(6)e202402644
|
|
S7905 |
3',3'-cGAMP
|
3',3'-cGAMP (3',3'-cyclic GMP-AMP, Cyclic GMP-AMP, cGAMP) activates the endoplasmic reticulum (ER)-resident receptor stimulator of interferon genes (STING), thereby inducing an antiviral state and the secretion of type I IFNs. |
|
|
A2938 |
Anti-IFNg (AMG 811)
|
Anti-IFNg (AMG 811) is a human monoclonal antibody (IgG1 isotype) that selectively targets human IFNgamma 7. It has potential to treat systemic lupus erythematosus (SLE). MW: 144.36 KD. |
|
|
A2105 |
Anti-mouse IFNγ-InVivo
|
The R4-6A2 monoclonal antibody reacts with mouse IFNγ (interferon gamma) which is a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. The R4-6A2 antibody has been shown to neutralize both natural and recombinant IFNγ. |
-
Nat Commun, 2024, 15(1):4913
-
iScience, 2024, 27(4):109545
|
|
E0448New |
RO8191
|
RO8191 (CDM-3008, RO4948191), an imidazonaphthyridine compound, is an orally active and potent agonist of interferon (IFN) receptor. RO8191 binds directly to the IFNα/β receptor 2 (IFNAR2), activating IFN-stimulated genes (ISGs) expression and the phosphorylation of JAK/STAT signaling. |
|
|
S6727 |
AX-024 HCl
|
AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. |
|
|
A2041 |
Emapalumab (anti-IFNγ)
|
Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory. |
-
Blood Adv, 2024, bloodadvances.2023012522
|
|
S6494 |
CCCP
|
CCCP (Carbonyl cyanide m-chlorophenyl hydrazone, Carbonyl cyanide 3-chlorophenylhydrazone), an oxidative phosphorylation inhibitor, is a protonophore mitochondrial uncoupler that increases membrane permeability to protons, leading to a disruption in the mitochondrial membrane potential. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP), the protonophore, can inhibits STING-mediated IFN-β production via disrupting mitochondrial membrane potential (MMP). |
- Nat Commun, 2024, 15(1):1785
- Nat Commun, 2024, 15(1):1669
- Redox Biol, 2024, 69:103002
|
|
S7259 |
FLLL32
|
FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM. FLLL32 inhibits the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.
|
- Cancer Commun -Lond), 2023, 43(10):1117-1142
- Microbiol Res, 2023, 276:127480
- Pathol Oncol Res, 2022, 28:1610273
|
|
S3544 |
VBIT-4
|
VBIT-4 is a voltage-dependent anion channel (VDAC) oligomerization inhibitor that decreases mitochondrial DNA (mtDNA) release, type I interferon (IFN) signaling, neutrophil extracellular traps, and disease severity in a mouse model of systemic lupus erythematosus. |
- Nature, 2023, 620(7973):374-380
- Nature, 2023, 620(7973):374-380
- Acta Pharm Sin B, 2023, 13(12):4765-4784
|
|
S3023 |
Bufexamac
|
Bufexamac(Bufexamic acid) is a COX inhibitor for IFN-α release with EC50 of 8.9 μM. |
- Biomedicines, 2024, 12(6)1203
- Int J Mol Sci, 2021, 22(9)4559
- Reprod Sci, 2021, 10.1007/s43032-021-00533-2
|
|
S5588 |
Creatine
|
Creatine (Methylguanidoacetic acid) is a nitrogenous organic acid that occurs naturally in vertebrates. It facilitates the recycling of adenosine triphosphate (ATP) primarily in muscle and brain tissue.Creatine can inhibits the JAK-STAT1 signal transmission by inhibiting the interaction of IFN-γ receptors with JAK2 in an ATP-independent manner, thereby inhibiting downstream pro-inflammatory gene expression. |
- Aging (Albany NY), 2022, 14(16):6796-6808
- Cancer Cell, 2021, S1535-6108(21)00445-1
- Histochem Cell Biol, 2021, 156(3):227-237
|
|
S3924 |
Ginsenoside Rb1
|
Ginsenoside Rb1 (Gypenoside Ⅲ) is a protopanaxadiol that has diverse in vitro and in vivo effects, including neuroprotective, anti-inflammatory, and anti-obesity actions. Ginsenoside Rb1, a main constituent of the root of Panax ginseng, inhibits Na+, K+-ATPase activity with IC50 of 6.3±1.0 μM. Ginsenoside also inhibits IRAK-1 activation and phosphorylation of NF-κB p65. Ginsenoside Rb1 reduces the expressions of TLR3, TLR4 and TRAF-6, and down-regulates the levels of TNF-α, IFN-β and iNOS. |
- J Biol Chem, 2024, 300(8):107542
- J Ethnopharmacol, 2021, S0378-8741(21)00169-0
- J Biol Chem, 2021, S0021-9258(21)00790-0
|
|
S8879 |
Deucravacitinib (BMS-986165)
|
Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases. |
- Nat Commun, 2024, 15(1):1718
- Nat Commun, 2024, 15(1):1337
- Nat Commun, 2024, 15(1):7165
|
|
S0437 |
SAR-20347
|
SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling. |
- Cancer Discov, 2023, 13(2):410-431
- Cancer Discov, 2023, 13(2):410-431
|
|
S1833 |
Butoconazole nitrate
|
Butoconazole nitrate (RS-35887) is an anti-fungal agent that inhibits PHA-stimulated release of cytokines-- IL-2, TNFα, IFN and GM-CSF from human peripheral blood lymphocytes (IC50 of 7.2 μg/mL, 14.4 μg/mL, 7.36 μg/mL and 7.6 μg/mL, respectively). |
|
|
E2982 |
IFN alpha-IFNAR-IN-1 hydrochloride
|
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor that inhibits the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) with IC50 value of 2-8 μM. |
|
|
S3827 |
Royal jelly acid
|
Royal jelly acid (10-Hydroxy-trans-2-decenoic acid, 10H2DA) is the principal lipid component in royal jelly which is the food for queen and larvae honeybees. It is involved in several treatment processes of autoimmune and inflammatory diseases, including inhibition of lipopolysaccharide (LPS)- and interferon (IFN)-γ-stimulated macrophage responses, inhibition of T-cell proliferation and anti-rheumatoid activity. |
|
|
S6727 |
AX-024 HCl
|
AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. |
|
|
A2121 |
Anti-mouse IFNAR-1-InVivo
|
Anti-mouse IFNAR-1-InVivo monoclonal antibody (Clone: MAR1-5A3) reacts with mouse IFNAR-1 (IFN alpha/beta receptor subunit 1). Anti-mouse IFNAR-1-InVivo has been shown to inhibit Type I IFN receptor signaling in vitro and in vivo. |
- Cell Rep, 2023, 42(1):112002
- Signal Transduct Target Ther, 2022, 7(1):137
|
|
A2152New |
Anti-mouse IFNγ (XMG1.2)-InVivo
|
Anti-mouse IFNγ (XMG1.2)-InVivo reacts with mouse IFNγ (interferon gamma) a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. |
- Antib Ther, 2024, 7(3):266-280
|
|
A2867 |
Fontolizumab (Anti-IFNg)
|
Fontolizumab (anti-IFNg) is a humanized monoclonal antibody directed against interferon-gamma (IFN-g) with immunomodulatory activity. MW: 144.8. |
|
|
A2460 |
Anifrolumab (Anti-IFNAR1)
|
Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD. |
|
|
A2461 |
Sifalimumab (Anti-IFNa1)
|
Sifalimumab (Anti-IFNa1) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. MW: 145.5 KD. |
|
|
A2664 |
Rontalizumab (Anti-IFNa1)
|
Rontalizumab (Anti-IFNa1) is a humanized IgG1 monoclonal antibody targets IFN-α. It can be used for the research of systemic lupus erythematosus. MW :150 KD. |
|
|
A2938 |
Anti-IFNg (AMG 811)
|
Anti-IFNg (AMG 811) is a human monoclonal antibody (IgG1 isotype) that selectively targets human IFNgamma 7. It has potential to treat systemic lupus erythematosus (SLE). MW: 144.36 KD. |
|
|
A2105 |
Anti-mouse IFNγ-InVivo
|
The R4-6A2 monoclonal antibody reacts with mouse IFNγ (interferon gamma) which is a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. The R4-6A2 antibody has been shown to neutralize both natural and recombinant IFNγ. |
- Nat Commun, 2024, 15(1):4913
- iScience, 2024, 27(4):109545
|
|
A2041 |
Emapalumab (anti-IFNγ)
|
Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory. |
- Blood Adv, 2024, bloodadvances.2023012522
|
|
S1537 |
Vadimezan (DMXAA)
|
Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3. |
- Mol Cancer, 2024, 23(1):186
- Nat Commun, 2024, 15(1):1750
- Cell Rep Med, 2024, 5(7):101648
|
|
S8133 |
Resiquimod (R-848)
|
Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2. |
- Int J Nanomedicine, 2024, 19:3589-3605
- Front Immunol, 2024, 15:1331480
- Biology (Basel), 2023, 12(2)318
|
|
S2259 |
Aloe-emodin
|
Aloe-emodin (NSC 38628, Rhabarberone) is an interferon-inducing agent with IC50 of about 1 μg/mL for JEV and of about 0.33 μg/mL for EV71. |
- PLoS One, 2019, 14(4):e0215664
- J Tradit Complement Med, 2015, 5(2):96-9
|
|
S8954 |
G10 (STING agonist-1)
|
G10 (STING agonist-1) is a novel human-specific STING agonist that triggers IFN regulatory factor 3 (IRF3)/ type I interferon (IFN)-associated transcription in human fibroblasts. STING agonist-1 (G10) potently reduces growth of Chikungunya virus (CHIKV) with IC90 of 8.01 μM and blocks replication of Alphavirus species Venezuelan Equine Encephalitis Virus (VEEV) with IC90 of 24.57 μM. |
- Int J Biol Sci, 2023, 19(11):3428-3440
|
|
S5020 |
Tilorone dihydrochloride
|
Tilorone dihydrochloride is a broad-spectrum, orally active antiviral agent that activates interferon production. It has antitumor, anti-inflammatory properties. |
|
|
S7904 |
2',3'-cGAMP Sodium Salt
|
2',3'-cGAMP Sodium Salt (2'-3'-cyclic GMP-AMP Sodium) is produced in response to DNA in the cytoplasm in mammalian cells and binds STING with high affinity and is an effective inducer of interferon-β (IFNβ). 2',3'-cGAMP binds to STING with Kd of 3.79 nM. |
- Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0
- Life Sci Alliance, 2024, 7(6)e202402644
|
|
S7905 |
3',3'-cGAMP
|
3',3'-cGAMP (3',3'-cyclic GMP-AMP, Cyclic GMP-AMP, cGAMP) activates the endoplasmic reticulum (ER)-resident receptor stimulator of interferon genes (STING), thereby inducing an antiviral state and the secretion of type I IFNs. |
|
|